Cargando…

A Mini-Review on Ceftaroline in Bacteremia Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Objective: The objective of this review is to describe the outcomes of patients treated with ceftaroline in the non-Food and Drug Administration (FDA) approved indication of methicillin-resistant Staphylococcus aureus (MRSA) infections in both pediatric and adult populations. Data sources: A systema...

Descripción completa

Detalles Bibliográficos
Autores principales: Lounsbury, Nicole, Reeber, Mary G., Mina, Georges, Chbib, Christiane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466573/
https://www.ncbi.nlm.nih.gov/pubmed/30897759
http://dx.doi.org/10.3390/antibiotics8010030
_version_ 1783411135146360832
author Lounsbury, Nicole
Reeber, Mary G.
Mina, Georges
Chbib, Christiane
author_facet Lounsbury, Nicole
Reeber, Mary G.
Mina, Georges
Chbib, Christiane
author_sort Lounsbury, Nicole
collection PubMed
description Objective: The objective of this review is to describe the outcomes of patients treated with ceftaroline in the non-Food and Drug Administration (FDA) approved indication of methicillin-resistant Staphylococcus aureus (MRSA) infections in both pediatric and adult populations. Data sources: A systematic overview was conducted by searching PubMed, Medline, and The Cochrane Library up to January 2019. Study selection and data extraction: All English-language clinical trials and case reports related to the efficacy of ceftaroline in new, not-yet-approved FDA indications in MRSA infections in pediatric or adult populations. Data synthesis: In the case of MRSA bacteremia (MRSAB) infections, three different randomized studies in pediatric patients showed effectiveness of ceftaroline. When used in the case of adult populations with MRSA bacteremia, a small trial of 16 patients showed 50% clinical success in patients with acute bacterial skin and skin structure infections versus 63% clinical success in patients with community-acquired bacterial pneumonia. Another case series of six refractory case reports showed 50% clinical success of ceftaroline in patients with MRSA. Conclusions: Although there are few case reports and limited data to date, ceftaroline fosamil should continue to be studied as an alternative therapy in MRSA infections in both pediatric and adult populations. Clinical success rates of ceftaroline were, in most cases, considered high when treating patients with MRSA infection. More clinical trials need to be studied. In the specific case of MRSA bacteremia, the treatment options remain few and ceftaroline should be extensively studied for the salvage treatment of MRSAB.
format Online
Article
Text
id pubmed-6466573
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64665732019-04-18 A Mini-Review on Ceftaroline in Bacteremia Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Lounsbury, Nicole Reeber, Mary G. Mina, Georges Chbib, Christiane Antibiotics (Basel) Review Objective: The objective of this review is to describe the outcomes of patients treated with ceftaroline in the non-Food and Drug Administration (FDA) approved indication of methicillin-resistant Staphylococcus aureus (MRSA) infections in both pediatric and adult populations. Data sources: A systematic overview was conducted by searching PubMed, Medline, and The Cochrane Library up to January 2019. Study selection and data extraction: All English-language clinical trials and case reports related to the efficacy of ceftaroline in new, not-yet-approved FDA indications in MRSA infections in pediatric or adult populations. Data synthesis: In the case of MRSA bacteremia (MRSAB) infections, three different randomized studies in pediatric patients showed effectiveness of ceftaroline. When used in the case of adult populations with MRSA bacteremia, a small trial of 16 patients showed 50% clinical success in patients with acute bacterial skin and skin structure infections versus 63% clinical success in patients with community-acquired bacterial pneumonia. Another case series of six refractory case reports showed 50% clinical success of ceftaroline in patients with MRSA. Conclusions: Although there are few case reports and limited data to date, ceftaroline fosamil should continue to be studied as an alternative therapy in MRSA infections in both pediatric and adult populations. Clinical success rates of ceftaroline were, in most cases, considered high when treating patients with MRSA infection. More clinical trials need to be studied. In the specific case of MRSA bacteremia, the treatment options remain few and ceftaroline should be extensively studied for the salvage treatment of MRSAB. MDPI 2019-03-20 /pmc/articles/PMC6466573/ /pubmed/30897759 http://dx.doi.org/10.3390/antibiotics8010030 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lounsbury, Nicole
Reeber, Mary G.
Mina, Georges
Chbib, Christiane
A Mini-Review on Ceftaroline in Bacteremia Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
title A Mini-Review on Ceftaroline in Bacteremia Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
title_full A Mini-Review on Ceftaroline in Bacteremia Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
title_fullStr A Mini-Review on Ceftaroline in Bacteremia Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
title_full_unstemmed A Mini-Review on Ceftaroline in Bacteremia Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
title_short A Mini-Review on Ceftaroline in Bacteremia Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
title_sort mini-review on ceftaroline in bacteremia patients with methicillin-resistant staphylococcus aureus (mrsa) infections
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466573/
https://www.ncbi.nlm.nih.gov/pubmed/30897759
http://dx.doi.org/10.3390/antibiotics8010030
work_keys_str_mv AT lounsburynicole aminireviewonceftarolineinbacteremiapatientswithmethicillinresistantstaphylococcusaureusmrsainfections
AT reebermaryg aminireviewonceftarolineinbacteremiapatientswithmethicillinresistantstaphylococcusaureusmrsainfections
AT minageorges aminireviewonceftarolineinbacteremiapatientswithmethicillinresistantstaphylococcusaureusmrsainfections
AT chbibchristiane aminireviewonceftarolineinbacteremiapatientswithmethicillinresistantstaphylococcusaureusmrsainfections
AT lounsburynicole minireviewonceftarolineinbacteremiapatientswithmethicillinresistantstaphylococcusaureusmrsainfections
AT reebermaryg minireviewonceftarolineinbacteremiapatientswithmethicillinresistantstaphylococcusaureusmrsainfections
AT minageorges minireviewonceftarolineinbacteremiapatientswithmethicillinresistantstaphylococcusaureusmrsainfections
AT chbibchristiane minireviewonceftarolineinbacteremiapatientswithmethicillinresistantstaphylococcusaureusmrsainfections